Sugi Predict

Sugi Predict / Compounds / SCHEMBL6324843

SCHEMBL6324843

SCHEMBL6324843

CNC(=O)Nc1ccc(OC)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.81
▸ NPC1 O15118 5/20 0.81
▸ SMN1; SMN2 Q16637 5/20 0.81
▸ SAE1 Q9UBE0 1/20 0.71
▸ UBA2 Q9UBT2 1/20 0.71
▸ MAPT P10636 3/20 0.66
▸ MEN1 O00255 2/20 0.66
▸ KMT2A Q03164 2/20 0.66
▸ KDM4E B2RXH2 2/20 0.66
▸ TP53 P04637 3/20 0.64
▸ ESR2 Q92731 1/20 0.64
▸ NOX1 Q9Y5S8 1/20 0.64
▸ TSHR P16473 1/20 0.62
▸ ALOX15 P16050 1/20 0.61
▸ HPGD P15428 1/20 0.61
▸ POLB P06746 2/20 0.60
▸ PKM P14618 1/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ CA12 O43570 1/20 0.60
▸ CA1 P00915 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11092496 0.90 RAB9A (1.00) RAB9ANPC1SMN1; SMN2SAE1UBA2
SCHEMBL10155599 0.85 ALDH1A1 (0.78) RAB9ANPC1SMN1; SMN2SAE1UBA2
SCHEMBL18810399 0.85 RAB9A (0.75) RAB9ANPC1SMN1; SMN2SAE1UBA2
SCHEMBL17628550 0.84 RAB9A (0.88) RAB9ANPC1SMN1; SMN2SAE1UBA2
SCHEMBL11875380 0.84 RAB9A (0.81) RAB9ANPC1SMN1; SMN2SAE1UBA2
SCHEMBL1897292 0.82 RAB9A (0.85) RAB9ANPC1SMN1; SMN2SAE1UBA2
SCHEMBL6394248 0.82 RAB9A (0.78) RAB9ANPC1SMN1; SMN2SAE1UBA2
SCHEMBL31325106 0.82 RAB9A (0.78) RAB9ANPC1SMN1; SMN2SAE1UBA2
SCHEMBL6827864 0.82 RAB9A (0.78) RAB9ANPC1SMN1; SMN2SAE1UBA2
SCHEMBL11106394 0.82 RAB9A (0.85) RAB9ANPC1SMN1; SMN2SAE1UBA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114867525-A Dihydrocyclopentaisoquinoline derivatives UCB生物制药有限责任公司 2022-08-05 — — CN claimed
CN-114867525-A Dihydrocyclopentaisoquinoline derivatives UCB生物制药有限责任公司 2022-08-05 — — CN disclosed
WO-2022003712-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-01-06 — — WO disclosed
EP-3189050-B1 ANTIVIRAL AGENTS AND USES THEREOF UNIV GRIFFITH (AU) 2020-02-05 — — EP disclosed
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof UNIVERSITY OF TSUKUBA (JP) 2019-07-16 — — US disclosed
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF UNIVERSITY OF TSUKUBA (JP) 2018-06-28 — — US disclosed
WO-2017180323-A1 PHENYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2017-10-19 — — WO disclosed
US-20170290809-A1 ANTIVIRAL AGENTS AND USES THEREOF GRIFFITH UNIVERSITY (AU) 2017-10-12 — — US disclosed
EP-2499148-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2017-01-18 — — EP disclosed
US-9464064-B2 HCV helicase inhibitors and methods of use thereof UNIVERSITY OF KANSAS (US) 2016-10-11 — — US disclosed
US-7157601-B2 Alkylated urea and triaminotriazine compounds and phase change inks containing same XEROX CORPORATION (US) 2007-01-02 — — US disclosed
WO-2006130686-A2 HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD SCHERING CORPORATION (US) 2006-12-07 — — WO disclosed
WO-2006130552-A2 METHODS OF TREATING HEPATITIS C VIRUS SCHERING CORPORATION (US) 2006-12-07 — — WO disclosed
WO-2006130688-A2 COMPOUNDS FOR INHIBITING CATHEPSIN ACTIVITY SCHERING CORPORATION (US) 2006-12-07 — — WO disclosed
WO-2006130554-A2 METHODS OF TREATING HEPATITIS C VIRUS SCHERING CORPORATION (US) 2006-12-07 — — WO disclosed
US-6894045-B2 Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-05-17 — — US disclosed
US-20030149059-A1 Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-08-07 — — US disclosed
WO-2003005969-A2 TETRAHYDROPURINONES AS CORTICOTROPIN RELEASING FACTOR BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2003-01-23 — — WO disclosed
US-5661153-A FOR TREATING ALLERGIES, ASTHMA, DERMATITIS, GRAFT REJECTIONS JAPAN ENERGY CORPORATION (JP) 1997-08-26 — — US disclosed
EP-0700908-A1 1-Arylpyrimidine derivatives and pharmaceutical use thereof JAPAN ENERGY CORPORATION (JP) 1996-03-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF HCRTR2, HCRTR1, NPSR1 RAB9A 2688/4885NPC1 733/4885SMN1; SMN2 1062/4885
US-20170290809-A1 ANTIVIRAL AGENTS AND USES THEREOF RNASE1, ENTPD5, ACE RAB9A 1505/4885NPC1 1326/4885SMN1; SMN2 3429/4885
US-20030149059-A1 Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands CRH, CRHR1, CRHR2 RAB9A 1282/4885NPC1 2751/4885SMN1; SMN2 3591/4885
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof HCRTR2, HCRTR1, NPSR1 RAB9A 2688/4885NPC1 733/4885SMN1; SMN2 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.